HbA1c control linked to recovery of ejection fraction in hospitalized HF patients with diabetes

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-11-13 14:30 GMT   |   Update On 2022-11-13 14:30 GMT

Researchers have found in a new study that glycemic control was associated with recovery of ejection fraction among hospitalized patients of heart failure with reduced ejection fraction with type 2 diabetes mellitus (T2DM). HbA1c control in type 2 diabetes patients with heart failure (HF), particularly in those with an ischemic etiology, is associated with subsequent partial or...

Login or Register to read the full article

Researchers have found in a new study that glycemic control was associated with recovery of ejection fraction  among hospitalized patients of heart failure with reduced ejection fraction with type 2 diabetes mellitus (T2DM).  HbA1c control in type 2 diabetes patients with heart failure (HF), particularly in those with an ischemic etiology, is associated with subsequent partial or complete recovery of ejection fraction (HFrecEF), researchers state in research published in the International Journal of Cardiology.

A substantial proportion of heart failure patients with reduced left ventricular ejection fraction (HFrEF) have experienced HFrecEF, defined as experienced partial or complete recovery of EF, and markedly improved clinical outcomes due to advances in medical treatment. Considering this, Chen Die Yang, Shanghai Jiao-Tong University School of Medicine, Shanghai, PR China, and colleagues aimed to examine the association between glycemic control and the incidence of HFrecEF in HFrEF patients with type 2 diabetes who are hospitalized.

For this purpose, the researchers consecutively enrolled 463 hospitalized T2DM patients with HFrEF. After about 12 months, an echocardiogram was performed. Patients with a definite EF improvement of≥10% and a second EF of> 40% were classified into HFrecEF. The patients who did not meet these criteria were labeled as having persistent HFrEF.

Based on HbA1c level tertiles, the patients were divided into three cohorts, and those with higher levels also had higher triglyceride levels, higher fasting glucose, and more frequent ischemic etiology. The cohorts were comparable for other characteristics and demographic (age, sex, blood pressure, cholesterol, and N-terminal pro-b-type natriuretic peptide levels, smoking, BMI, renal function, and history of hypertension).

The study led to the following findings:

· 44.5% of T2DM patients developed HFrecEF during the 12-month follow-up.

· HFrecEF patients had significantly lower HbA1c levels than those with persistent HFrEF (6.5% vs. 6.7%), especially in those with an ischemic etiology.

· HbA1c levels were inversely associated with changes in ejection fraction during follow-up.

· Every 1% increase in HbA1c led to a 17.4% lower likelihood of HFrecEF after multivariate adjustment.

· Patients with poor glycemic control having an HbA1c > 7.1% had a 52.0% reduced risk of HFrecEF versus patients with good glycemic control (HbA1c ≤ 6.2%).

Limitations of the study were that the data are from a single center and its retrospective design. Also, there was selection bias, and the sample size was underpowered.

Findings imply that the uncontrolled HbA1c level is linked with compromised HFrecEF development in T2DM patients with heart failure, particularly those with an ischemic etiology.

Reference:

Yang CD, Aihemaiti M, Quan JW, Chen JW, Shu XY, Ding FH, Shen WF, Lu L, Zhang RY, Pan WQ, Wang XQ. HbA1c level is associated with the development of heart failure with recovered ejection fraction in hospitalized heart failure patients with type 2 diabetes. Int J Cardiol. 2022 Sep 16:S0167-5273(22)01339-0.

doi: 10.1016/j.ijcard.2022.09.029

. Epub ahead of print. PMID: 36116615.


Tags:    
Article Source : International Journal of Cardiology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News